Corporate Member AstraZeneca - NEW Approval

Corporate Member AstraZeneca - NEW Approval

IMFINZI™ (durvalumab)
June, 2017

The US Food and Drug Administration (FDA) has granted accelerated approval to IMFINZI™ (durvalumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or whose disease has progressed within 12 months of receiving platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery.

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members